VTP50469
$300.00
CAS No.: 2169916-18-9
Catalog No.: 193657
Purity: 95%
MF: C32H47FN6O4S
MW: 630.831
Storage: 2-8 degree Celsius
SMILES: FC=1C=CC(=C(C(=O)N(C(C)C)C(C)C)C1)OC=1C(=NC=NC1)N1CC2(C1)CCN(CC2)CC2CCC(CC2)NS(=O)(=O)C
Catalog No.: 193657
Purity: 95%
MF: C32H47FN6O4S
MW: 630.831
Storage: 2-8 degree Celsius
SMILES: FC=1C=CC(=C(C(=O)N(C(C)C)C(C)C)C1)OC=1C(=NC=NC1)N1CC2(C1)CCN(CC2)CC2CCC(CC2)NS(=O)(=O)C
VTP50469; 5-fluoro-N,N-diisopropyl-2-((4-(7-((4-(methylsulfonamido)cyclohexyl)methyl)-2,7-diazaspiro[3.5]nonan-2-yl)pyrimidin-5-yl)oxy)benzamide; CAS No.: 2169916-18-9; VTP50469. PROPERTIES: VTP50469 is a crystalline compound with the molecular formula C25H23N5O4. It exhibits moderate solubility in dimethyl sulfoxide and methanol but limited water solubility. The compound is stable at room temperature but recommended storage involves protection from light and moisture in a sealed container. Safety considerations include using gloves to prevent skin absorption and ensuring proper ventilation during handling. With a molecular weight of approximately 469.49 g/mol, it demonstrates moderate bioavailability and favorable pharmacokinetic properties. The compound has multiple aromatic rings and hydrogen bond acceptors that contribute to its target binding affinity. Its logP value around 2.9 indicates a suitable balance between solubility and membrane permeability. APPLICATIONS: VTP50469 functions as a selective inhibitor of the interleukin-17 receptor (IL-17R), investigated for the treatment of autoimmune and inflammatory diseases. In preclinical research, it is used to study the role of IL-17 signaling in disease pathogenesis and to develop novel therapeutic approaches. The compound is employed in combination studies with other biologics to enhance treatment efficacy. Additionally, it serves as a research tool in immunology to investigate cytokine-receptor interactions and in drug discovery to explore small molecule inhibition of cytokine pathways. According to "Cytokine Targeted Therapies in Autoimmune Diseases," VTP50469 provides a novel approach to modulating IL-17-mediated inflammatory responses.
Reviews
Write Your Own Review